Diltiazem extended-release capsules recalled for manufacturing impurity
Glenmark Pharmaceuticals is recalling 4,704 bottles of Diltiazem Hydrochloride extended-release capsules 90mg due to manufacturing contamination with an impurity above FDA limits. Two lot numbers distributed nationwide are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II pharmaceutical recall involves the presence of an impurity above FDA regulatory limits in a cardiac medication. The manufacturing defect exceeding regulatory thresholds meets criteria for a risk-of-harm product, warranting High severity despite no reported illnesses or injuries to date.
Plain-English summary
Glenmark Pharmaceuticals Inc. is recalling 4,704 bottles of Diltiazem Hydrochloride Extended-Release Capsules 90mg due to a cGMP (current Good Manufacturing Practice) deviation. The recall was initiated because of the presence of N-nitroso-Desmethyl-Diltiazem impurity at levels above FDA recommended interim limits.
The affected product includes two lot numbers: 17222452 (expiration 11/30/2024) and 17230607 (expiration 02/28/2025). The capsules were distributed nationwide in the United States.
Diltiazem is a prescription medication used to treat high blood pressure and certain heart conditions. Consumers who are taking this medication should not discontinue use without consulting their healthcare provider. Anyone with bottles matching the affected lot numbers should contact their pharmacy for a refund or replacement.
The recalled product
- Product
- DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE)
- Brand
- DILTIAZEM HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Prescription Medication
- Hazard
- manufacturing-deviation
- pharmaceutical-impurity
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 17222452
- Exp Date 11/30/2024
- 17230607
- Exp Date 02/28/2025.
UPCs (3)
- 0316714555010
- 0316714553016
- 0316714554013
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DILTIAZEM HYDROCHLORIDE
- HighGlenmark Diltiazem Extended-Release Capsules recalled for manufacturing deviations
FDA (Drugs) · 2025-04-16
- HighDiltiazem Hydrochloride Capsules Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Extended-Release Capsules Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Capsules Recalled Due to Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighPrescription Drug Diltiazem Hydrochloride Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27